Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.
Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.
复制标题
DOI:
10.4049/jimmunol.1200553
复制
发表时间:
2012-06-15
期刊:
影响因子:
--
通讯作者:
Tomlinson S
中科院分区:
文献类型:
--
作者:
Schepp-Berglind J;Atkinson C;Elvington M;Qiao F;Mannon P;Tomlinson S
Complement plays a key role in the pathophysiology of many inflammatory diseases, and here we investigated the role of complement in the pathogenesis of inflammatory bowel disease (IBD). Compared to wild type (wt) mice, mice deficient in C3 or factor B (fB) were protected from acute DSS-induced colitis. C1q/MBL double deficient mice, however, exhibited more severe colitis than wt mice. When mice were allowed to recover after DSS treatment, all C1q/MBL-/- mice died by day 2 of recovery period and, surprisingly, all C3-/- and fB-/- mice died by day 5. Serum endotoxin levels were significantly increased in complement deficient mice prior to death, particularly in C1q/MBL-/- mice, and antibiotic treatment prevented the lethal effect of DSS in all complement deficient mice. In contrast to complement deficiency, targeted complement inhibition with either CR2-Crry (blocks all pathways at C3 activation) or CR2-fH (blocks alternative pathway), was highly protective at treating established acute colitis. Endotoxin levels remained low in complement inhibited mice, and complement inhibition also reduced inflammatory cytokines, leuckocyte infiltration and tissue injury, while improving wound repair and mucosal healing. CR2-fH provided more effective protection than CR2-Crry. Thus, complement has both pathogenic and protective roles in acute DSS-induced colitis, and whereas the alternative pathway appears to play a key role in tissue inflammation and injury, the classical/lectin pathway provides important protection in terms of host defense and wound repair. Targeted inhibition of the alternative pathway may represent a therapeutic modality for treating acute phases of IBD.
登录
查看更多内容
DOI:
10.4049/jimmunol.181.11.8068
发表时间:
2008-12-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Huang Y;Qiao F;Atkinson C;Holers VM;Tomlinson S
通讯作者:
Tomlinson S
DOI:
10.4049/jimmunol.1002741
发表时间:
2011-03-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Dahlke K;Wrann CD;Sommerfeld O;Sossdorf M;Recknagel P;Sachse S;Winter SW;Klos A;Stahl GL;Ma YX;Claus RA;Reinhart K;Bauer M;Riedemann NC
通讯作者:
Riedemann NC
影响因子:
6
作者:
Stahl, GL;Xu, YY;Zhao, H
通讯作者:
Zhao, H
影响因子:
3.2
作者:
Hoffmann, Christina;Hoffmann, Peter;Weimann, Andreas
通讯作者:
Weimann, Andreas
影响因子:
64.8
作者:
Prodeus, AP;Zhou, XN;Carroll, MC
通讯作者:
Carroll, MC